Inactivated and subunit vaccines against porcine reproductive and respiratory syndrome: Current status and future direction. Issue 27 (17th June 2015)

• Record Type: Journal Article
• Authors: Renukaradhya, Gourapura J.; Meng, Xiang-Jin; Calvert, Jay G.; Roof, Michael; Lager, Kelly M.
• Is Part Of: Vaccine. Volume 33:Issue 27(2015)
• Page Start: 3065
• Page End: 3072
• Publication Date: 2015-06-17
• Subjects: Porcine reproductive and respiratory syndrome virus (PRRSV) -- Inactivated/killed PRRSV -- Immunity -- Cross-protection -- Delivery system; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.04.102
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: PRRSV is an important pig disease. Killed vaccines are required to control PRRS. Killed/subunit PRRSV vaccine studies are reviewed. Abstract: Within a few years of its emergence in the late 1980s, the PRRS virus had spread globally to become the foremost infectious disease concern for the pork industry. Since 1994, modified live-attenuated vaccines against porcine reproductive and respiratory syndrome virus (PRRSV-MLV) have been widely used, but have failed to provide complete protection against emerging and heterologous field strains of the virus. Moreover, like many other MLVs, PRRSV-MLVs have safety concerns including vertical and horizontal transmission of the vaccine virus and several documented incidences of reversion to virulence. Thus, the development of efficacious inactivated vaccines is warranted for the control and eradication of PRRS. Since the early 1990s, researchers have been attempting to develop inactivated PRRSV vaccines, but most of the candidates have failed to elicit protective immunity even against homologous virus challenge. Recent research findings relating to both inactivated and subunit candidate PRRSV vaccines have shown promise, but they need to be pursued further to improve their heterologous efficacy and cost-effectiveness before considering commercialization. In this comprehensive review, we provide information on attempts to develop PRRSV inactivated and subunit vaccines. These includes various virus inactivation strategies, adjuvants, nanoparticle-based vaccine delivery systems, DNA vaccines, and recombinant subunit vaccines produced using baculovirus, plant, and replication-deficient viruses as vector vaccines. Finally, future directions for the development of innovative non-infectious PRRSV vaccines are suggested. Undoubtedly there remains a need for novel PRRSV vaccine strategies targeted to deliver cross-protective, non-infectious vaccines for the control and eradication of PRRS.